James M.  Musser, MD, PhD

James M. Musser, MD, PhD

Houston Methodist

Genomic Medicine & Infectious Disease and Pathology

Expertise:

Dr. James M. Musser his medical training at the University of Rochester and his residency in laboratory medicine at the University of Pennsylvania. He also completed postdoctoral research in molecular evolutionary genetics at Pennsylvania State University. Musser conducts research that focuses on the molecular basis of host-pathogen interactions in group A Streptococcus and Mycobacterium tuberculosis. His areas of expertise include Mycobacterium tuberculosis, Group A Streptococcus, infectious disease and antibiotic-resistant bacteria. 

 

No Research/Citations

Genome sequencing reveals widespread COVID-19 infection in white-tailed deer

Houston Methodist’s SARS-CoV-2 genome sequencing team has partnered on a study led by Penn State that revealed 80% of white-tailed deer sampled across Iowa at the height of the 2020-2021 deer-hunting season tested positive for the SARS-CoV-2 virus. Analysis of the virus genome sequences revealed infections were likely the result of multiple human-to-deer transmission “spillover” events followed by deer-to-deer transmission from April 2020 through January 2021.
09-Nov-2021 08:55:11 AM EST

Houston Methodist study reveals COVID-19 UK variant cases doubling weekly in Houston

Houston Methodist infectious disease pathologists have discovered new COVID-19 cases caused by the SARS-CoV-2 UK B.1.1.7 variant are doubling weekly. By mid-March the number increased sharply to 648 cases from 305 just a week earlier. The findings come from the latest batch of 8,857 virus genomes sequenced from patients with positive COVID-19 tests in the first two months of 2021, representing 94% of Houston Methodist cases.
31-Mar-2021 06:00:52 PM EDT

Houston Methodist finds multiple cases of significant coronavirus mutations, including Brazil strain

Houston Methodist has sequenced more than 20,000 of Houston’s coronavirus genomes since the start of the pandemic and leads the SARS-CoV-2 genome sequencing efforts in the U.S. In the most recent batches of genomes, the U.K., South Africa, Brazil, California and New York variants were detected.
02-Mar-2021 03:05:43 PM EST

60-day follow-up of 300+ COVID-19 patients demonstrates convalescent plasma therapy is safe and effective

A follow-up Houston Methodist study of 351 COVID-19 patients treated with convalescent plasma therapy concludes those patients receiving convalescent plasma with a very high antibody content – or high titer – within 72 hours of hospitalization were significantly more likely to survive SARS-CoV-2 coronavirus infection. The results confirm and extend scientific evidence from an earlier interim study and show transfusion of high-titer convalescent plasma has maximum beneficial effect if given within 44 hours of hospitalization.
06-Oct-2020 03:05:36 PM EDT

Preliminary study of 300+ COVID-19 patients suggests convalescent plasma therapy effective

A preliminary analysis of an ongoing study of more than 300 COVID-19 patients treated with convalescent plasma therapy at Houston Methodist suggests the treatment is safe and effective. The results, published in The American Journal of Pathology, represent one of the first peer-reviewed publications in the country assessing efficacy of convalescent plasma and offer valuable scientific evidence that transfusing critically ill COVID-19 patients with high antibody plasma early in their illness reduced the mortality rate.
12-Aug-2020 06:30:44 PM EDT

Study finds COVID-19 convalescent plasma therapy safe, with 76% patients improving

The first convalescent plasma transfusion trial results from Houston Methodist have been published. Of the study’s 25 patients, 19 have improved and 11 discharged. With no adverse side effects caused by the therapy, the study concluded convalescent plasma is a safe treatment option for patients with severe COVID-19. This is the first peer-reviewed publication in the U.S. of convalescent plasma therapy results for COVID-19.
07-Jun-2020 10:05:27 PM EDT

Study finds COVID plasma therapy safe, with 76% patients improving

The first convalescent plasma transfusion trial results from Houston Methodist have been released. Of the 25 patients in the study, 19 have improved and 11 have been discharged. With no adverse side effects caused by the therapy, the study concluded that convalescent plasma is a safe treatment option for patients with severe COVID-19. This is the largest cohort assessed for outcomes related to convalescent plasma therapy for COVID-19.
13-May-2020 12:05:21 PM EDT

Houston Methodist researchers find telling clues in virus genes from COVID-19 patients

Houston Methodist released gene sequencing results from the first strains of the virus causing COVID-19 disease in Houston. Results reveal multiple introductions of SARS-CoV-2 into Houston followed by rapid community spread. No evidence was found of mutations making any strains of the virus more severe. Pathologists analyzed genomes of 320 SARS-CoV-2 strains collected from COVID-19 patients, making this the largest sample of SARS-CoV-2 genes sequenced from patients in the southern U.S.
08-May-2020 02:40:28 PM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video

close
0.07515